Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07575893 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

Study acronym: REACH-CD30
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Dec 1, 2026 to Oct 1, 2026v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.
Trial Details
NCT Number NCT07575893
Lead Sponsor New York Medical College
Collaborators: University of North Carolina, Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Classical Hodgkin Lymphoma
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov